TITLE

Agricultural biotechnology

AUTHOR(S)
Fairley, Peter
PUB. DATE
July 1998
SOURCE
Chemical Week;7/22/1998, Vol. 160 Issue 27, p16
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the expansion of the 1993 cross-licensing agreement between Novartis and Dow subsidiary Mycogen. Coverage of the licensing agreement; Products to be marketed by the companies; Comments from Michael Muston, president of Mycogen's seeds unit.
ACCESSION #
910544

 

Related Articles

  • Monsanto loses dispute.  // Chemical Market Reporter;07/06/98, Vol. 254 Issue 1, p5 

    Reports on Monsanto Co.'s loss of a patent dispute over engineered corn seed with Mycogen Corp. and Novartis Corp.

  • Court Overturns $175 Million Damage Award to Mycogen. Sissell, Kara // Chemical Week;7/5/2000, Vol. 162 Issue 26, p23 

    Reports that the California Court of Appeals has overturned a damage award to Mycogen company on a patent case. Details on the licensing rights dispute between Mycogen and Monsanto company.

  • Tech startup of the month. Peterson, Eric // ColoradoBiz;May2002, Vol. 29 Issue 5, p49 

    Features the GlobeImmune Inc. in Denver, Colorado. Production of vaccine from brewer's yeast proteins; Focus on the HIV disease; Licensing agreement with Novartis.

  • OTHER NEWS TO NOTE.  // BioWorld Today;6/7/2010, Vol. 21 Issue 108, p6 

    This section offers news briefs concerning the biotechnology industries, which include the licensing agreement between Ascalon International Inc. and CerRx Inc., the agreement between Emisphere Technologies Inc. and Novartis AG and preclinical data on the dual agonist of Toll-like Receptor 7...

  • Novartis in AMD deal.  // Optometry Today;5/23/2014, Vol. 54 Issue 10, p5 

    The article reports on a licensing agreement between pharmaceutical companies Novartis and Ophthotech concerning the non-U.S. commercial rights to Novartis' wet age-related macular degeneration (AMD) drug Fovista.

  • Debiopharm signs licensing agreement with Novartis.  // PharmaWatch: Biotechnology;Mar2010, Vol. 9 Issue 3, p16 

    The article reports that Swiss biopharmaceutical firm Debiopharm Group has signed a licensing agreement with Novartis AG for the commercialization, manufacture and development of Debio 025, a selective, cyclophilin inhibitor with a potent antihepatitis C virus (HCV) effect.

  • Novartis Acquires Hepatitis C Franchise.  // Chemical Market Reporter;3/31/2003, Vol. 263 Issue 13, p2 

    Focuses on the stakes acquired by Novartis AG from biotechnology company Indenix in Cambridge, Massachusetts. Terms of the deal; Payments made for the licensing of hepatitis drugs.

  • Novartis' Lens Effect.  // Micro Mart;7/24/2014, Issue 1321, p37 

    The article reports that Internet search company Google and Swiss company Novartis have signed an agreement allowing to license Google X Labs' smart lens technology.

  • University of Pennsylvania and Novartis form alliance to expand use of personalized T cell cancer therapy.  // Biomedical Market Newsletter;8/1/2012, Vol. 21, p1 

    The article informs that the University of Pennsylvania, Philadelphia, Pennsylvania and Novartis AG have announced an exclusive global research and licensing agreement to study and commercialize novel cellular immunotherapies.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics